BKBikash Ranjan Kar

Bikash Ranjan Kar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bikash Ranjan Kar has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plectin (PLEC)-Related Intermediate Epidermolysis Bullosa Simplex without Extracutaneous Involvement with Response to Dapsone

    by Anisha Biswal, Bikash Ranjan Kar, Rahul Mahajan, Liza Mohapatra, Anoop Kumar

    Plectinopathies, the spectrum of diseases caused by plectin gene (PLEC) mutations, have a wide range of manifestations, mostly extracutaneous, like pyloric atresia, muscular dystrophy, and cardiomyopathy, along with cutaneous tense blistering. Differently spliced exons give rise to various isoforms, which have definitive functions in different cell types and tissues. We report a case of a 14-year-old girl presenting with features of tense pruritic vesicles and bullae on extremities and trunk since childhood. She was diagnosed with intermediate epidermolysis bullosa simplex, having nonsense PLEC mutation at exon 1. The uniqueness of the case is the absence of extracutaneous manifestations and her dramatic response to dapsone.

  • Open Access

    Management of Pustular Psoriasis; The Way Ahead

    by Shrichand G. Parasramani, Bikash R. Kar, Sushil Tahiliani, Anchala Parthasarathi, Shekhar Neema, Satyaki Ganguly, Dharshini Sathishkumar, K Venkatachalam, Haritha Komeravelli, Jayakar Thomas

    Pustular psoriasis is a specialized variant of psoriasis which can be life threatening if not treated at the earliest. The pathogenesis has been recently linked to the role of interleukin 36. Apart from the corticosteroids, systemic antipsoriatics like acitretin, cyclosporine and methotrexate have been used with some success though unpredictable. With recent identification of role of IL-36 in the pathogenesis of pustular psoriasis, biologics targeting the IL-36 receptors have been used to manage the situation with high degree of success. This narrative review deals with the recent concepts of pathogenesis of pustular psoriasis as well as the current management scenario.

  • Open Access

    Small Molecules in the Management of Psoriasis and Psoriatic Arthritis

    by Venkata Chalam Konakanchi, Bikash R. Kar, Dharshini Sathishkumar, Sushil Tahiliani, Anchala Parthasarathi, Shekhar Neema, Satyaki Ganguly, Shrichand G. Parasramani, Haritha Komeravelli, Jayakar Thomas

    Psoriasis is a common chronic, immune-mediated inflammatory skin disease associated with various comorbidities. Managing psoriasis is often challenging as the therapy is decided based on the area of the disease, associated comorbidities and impairment in quality of life, besides the patient’s preference. Making progress in the development of new molecules that can be used topically or orally, effectively controlling the disease with minimal side effects and providing long-lasting remissions are the needs of the hour. Recent developments in understanding the complexities of the pathogenesis of psoriasis have resulted in the reinforcement of treatment modalities, leading to the evolution of various biologics and small-molecule inhibitors. In comparison with biologics, both patients and treating physicians prefer small molecules for various reasons such as avoiding injections and side effects that are associated with biologics biologics. Moreover small molecules are economical than biologics. Newer small molecules, both topical and oral, are promising additions to the therapeutic arsenal in the management of psoriasis in the future.


  • Open Access

    Biomarkers in Psoriasis: The Future of Personalised Treatment

    by Bikash R. Kar, Dharshini Sathishkumar, Sushil Tahiliani, Anchala Parthasarathi, Shekhar Neema, Satyaki Ganguly, K. Venkatachalam, Shrichand G. Parasramani, Haritha Komeravelli, Jaykar Thomas

    Psoriasis is a chronic and complex immune-mediated papulosquamous disease affecting almost 2% of the world population. The interaction between a genetically predisposed individual and environmental triggers leads to a vicious cycle involving autoreactive T cells, dendritic cells, keratinocytes and dermal cells. Up to 40% of the psoriasis cases develop disabling psoriatic arthritis and an equal number of patients also tend to develop metabolic syndrome as well as cardiovascular comorbidities; hence, this is no more considered to be a disease limited to skin only. Being a systemic disease, there is an urgent need to develop potential biomarkers for the assessment of disease severity, prediction of outcome of the therapeutic intervention and association with various systemic comorbidities. Diverse genetic markers not only function as predictors of diseases pathogenesis, but also help to predict development of psoriasis and psoriatic arthritis. Personalised medicine is customising the therapeutic needs of a psoriasis patient and improving the outcome as per the hints we receive from the various biomarkers. This review deals with the list of potential biomarkers proposed to be useful in psoriasis, though there is limited data validating their routine use in clinical practice and the progress so far made in the field of precision medicine for psoriasis.


  • Open Access

    Comparison of Efficacy of Luliconazole 1% w/w Cream Versus Amorolfine 0.25% w/w Cream in the Treatment of Tinea cruris: A Single-center, Randomized, Double-blind, Non-inferiority Study

    by Abhipsa Samal, Bhabani S.T.P. Singh, Bikash Ranjan Kar, Liza Mohapatra

    Dermatophytosis is a superficial fungal infection involving the keratinized tissues. Limited dermatophytosis is usually treated with topical antifungals. Amorolfine and luliconazole are relatively newer and superior topical antifungals much in use in recent times. To study the therapeutic efficacy and safety of luliconazole 1% and amorolfine 0.25% cream in patients with tinea cruris. A single-center, randomized, double-blind, non-inferiority study comparing luliconazole and amorolfine was conducted on patients with localized tinea cruris. 81 patients completed the study, with 40 patients treated with luliconazole and 41 patients treated with amorolfine. Both groups of patients were followed up at the end of 2 weeks. No statistically significant difference was found between luliconazole and amorolfine regarding improvement in erythema, scaling, pruritus, and mycological cure. Both the medications were safe and well tolerated by the patients. The duration of the study was short, and there was no long-term follow-up. Amorolfine is not inferior to luliconazole in treating limited tinea cruris.


  • Open Access

    Comparison of Efficacy and Safety between Super-bioavailable Itraconazole and Conventional Itraconazole in the Treatment of Tinea Infection of Glabrous Skin – A Randomised Observer-blinded Pilot Study

    by Liza Mohapatra, Nibedita Dixit, Ishan Agrawal, Bikash Ranjan Kar, Bhabani S.T.P. Singh

    Itraconazole is now being used as the first line drug for dermatophytosis. Complete clinical and mycological cure are not achieved in some cases. The Super Bioavailable (SB) formulation is being marketed as a better formulation of drug in terms of bioavailability. To compare the efficacy and safety of SB and conventional Itraconazole in treatment of dermatophytosis. We compared the efficacy and safety of conventional itraconazole 100 mg twice daily with SB itraconazole 50 mg twice daily in dermatophytosis for two weeks. A convenient sample size of 30 was taken in each group. There was no significant difference in clinical parameters like erythema, scaling, number of papules between the two groups. Change in mean haemoglobin, total leucocyte count, platelet count, liver enzymes SGOT and SGPT and ALP did not differ significantly between the groups. There was no significant difference in the change in KOH status between the groups. There was no significant difference in clinical and mycological clearance between the conventional and the Super Bioavailable itraconazole at the end of two weeks in case of dermatophytosis of glabrous skin.


  • Open Access

    Dermoscopic Findings of Recurrent Herpetic Whitlow in a Child

    by Ishan Agrawal, Bhabani Stp Singh, Bikash Ranjan Kar

    Citation: Agrawal I, Singh BS, Kar BR. Dermoscopic Findings of Recurrent Herpetic Whitlow in a Child. Dermatol Pract Concept. 2022;12(2):e2022052. DOI: https://doi.org/10.5826/dpc.1202a52 Accepted: August 5, 2021; Published: April 2022 Copyright: ©2022 Agrawal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication Corresponding author: Ishan Agrawal, Department of Dermatology, IMS and SUM Hospital, SOA University, Bhubaneswar, India – 751003. Email: ishanagrawal1995@gmail.com Keywords : herpetic whitlow, recurrent herpes, dermoscopy This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Open Access

    Cutaneous small‐vessel vasculitis following COVID‐19 vaccine

    by Bikash Ranjan Kar, Bhabani Stp Singh, Liza Mohapatra, Ishan Agrawal


  • Open Access

    Fractional carbon dioxide laser versus fractional carbon dioxide laser with autologous intralesional platelet-rich plasma in the treatment of stable, non-segmental vitiligo: A randomized comparative study

    by BikashR Kar, Annie Raizada, Maitreyee Panda, BhabaniSTP Singh

    The treatment of vitiligo is often challenging and requires a multi-modality approach. Fractional carbon dioxide (FCO2) laser has been studied as an adjuvant therapy in cases of vitiligo. Autologous platelet-rich plasma (PRP) is rich in growth factors, which may contribute to the growth of melanocytes, and thus help in the repigmentation of vitiligo patches. We aimed to study the combination of these two modalities for the treatment of vitiligo. The aim of this study was to compare the efficacy and safety of FCO2 laser with PRP and FCO2 laser alone as an adjuvant therapy in stable non-segmental vitiligo (NSV) patients. A prospective, randomized, comparative, open-label interventional study was carried out for a period of 18 months from December 2017 to June 2019, at a tertiary care hospital. Seventy patients with stable, NSV were assessed for eligibility; 66 patients were randomized equally into two groups. Group A received treatment with FCO2 laser with intralesional PRP, whereas Group B was treated with FCO2 laser alone. Patients in both the groups were treated with one therapy session and were followed up monthly for a period of 3 months. All the patients received topical psoralen with ultraviolet A (UVA) PUVA-sol treatment. Baseline and monthly assessments were done by VITILIGO AREA SEVERITY INDEX and standardized photographs. VASI score reduction was significantly more in the Group A with (mean ± standard deviation [SD]) 9.5 ± 0.22, 5.8 ± 1.12, and 3.6 ± 1.81 as compared to Group B 11.9 ± 2.83, 9.9 ± 3.11, and 8.9 ± 3.46 at each subsequent follow-up visits, respectively. Side effects such as burning sensation, erythema, and crusting were seen less frequently and lasted for a short period in Group A in comparison to those in Group B. Combination of FCO2 laser and autologous intralesional PRP has a synergetic effect in treating patients with vitiligo as an adjuvant therapy with minimal adverse effects.


  • Open Access

    Narrow-band UVB phototherapy does not consistently improve quality of life in psoriasis patients: A prospective observational study from Eastern India

    by BikashR Kar, Shweta Arora

    Psoriasis with minimal side-effects compared to other systemic therapies. Objectives: To study whether NBUVB phototherapy administration improves QoL in plaque-type psoriasis and to find the correlation between clinical severity of psoriasis and patients’ QoL by using psoriasis area severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) tools before and after NBUVB phototherapy. Materials and Methods: Thirty-seven patients with plaque psoriasis involving >10% of body surface area (BSA) underwent NBUVB phototherapy thrice weekly for 36 sessions. Clinical severity of psoriasis was assessed by PASI and impact of psoriasis on quality of life by DLQI and PDI. Assessment was done at the baseline, 18th, and 36th session. Results: After 36 sessions of NBUVB phototherapy, mean reduction in PASI was 79.6% which was statistically significant. On the other hand, DLQI and PDI did not show significant improvement and did not correlate with PASI. Conclusion: NBUVB phototherapy reduces clinical severity of psoriasis. However, clinical severity and QoL impairment is independent of one another. DLQI and PDI do not improve proportionate to clinical improvement....